Jubilant Pharmova Ltd reported a 21% year-on-year increase in revenue to Rs 2,370 crore for the second quarter of FY27, driven by broad-based growth across all business segments.
However, higher operating expenses, increased depreciation and the unavailability of high-margin radiopharmaceutical products weighed heavily on profitability.
The company's reported net profit (PAT) plunged 74% to Rs 31 crore in Q2 FY27, compared with Rs 120 crore in the corresponding quarter last year. EBITDA declined 27% to Rs 255 crore from Rs 351 crore a year ago.
Profitability also came under pressure, with EBITDA margin contracting to 10.7% from 17.8% in Q2 FY26. Reported PAT margin fell to 1.3% from 6.1%.
Total income rose 21% to Rs 2,384 crore during the quarter, against Rs 1,976 crore in the year-ago period.
For the first half of FY27, Jubilant Pharmova posted revenue of Rs 4,599 crore, registering 19% growth over Rs 3,867 crore in H1 FY26. However, EBITDA declined 20% to Rs 523 crore, while reported PAT dropped 61% to Rs 87 crore.
Commenting on the performance, Chairman Shyam S Bhartia and Co-Chairman and Non-Executive Director Hari S Bhartia said, “We are pleased to announce revenue of Rs. 2,370 Cr. for Q2’FY27, which reflects a solid growth of 21% on YoY basis. Revenue growth is broad based across all our business segments, but particularly strong in CDMO Sterile Injectables on the back of technology transfer revenues from the new and third line.
"EBITDA for the quarter stands at Rs. 255 Cr. EBITDA margins declined year-on-year, primarily due to the unavailability of high-margin SPECT radiopharmaceutical products in the Radiopharmaceuticals business. Additionally, margins were impacted by higher operating expenses, including incremental remediation costs at the CMO Montreal facility. Reported PAT for the period stands at Rs. 31 Cr. PAT margins decreased due to lower operating profitability and increase in depreciation."
They added: “During Q2’FY27, we saw continued growth momentum in the Ruby-Fill installs. We also saw the release of Commercial SPECT radiopharmaceutical product from CMO Montreal, post the restart of production. We signed an agreement with a large radiopharmaceutical player to distribute one of the leading PET diagnostic products through our new PET pharmacies.
"In the Allergy Immunotherapy business, we witnessed increase in demand from both markets, US and Outside US. In the CDMO Sterile Injectables business, we signed a master services agreement with a large innovator pharma company for manufacturing and commercial supply of one of the largest oncology products. In the CRDMO business, we expect increase in revenues from Biotech customer segment and custom manufacturing revenue line.
"In the Generics Business, we saw sharp revenue growth on the back of multiple new products launched in FY27. Lastly, in our Proprietary Novel drugs business, we presented initial clinical data from JBI-802 Phase 1/2 clinical trial, demonstrating rapid, sustained and durable, dose-dependent reductions in platelet counts with a manageable safety profile. We are also pleased to share that we have successfully raised Rs. 800 Cr. through Non-convertible debentures. The proceeds shall be utilised towards refinancing of debt and capex.”
Despite the decline in quarterly profitability, the company highlighted operational progress across its businesses.
In Radiopharmaceuticals, Jubilant Pharmova reported continued growth in Ruby-Fill installations and the release of a commercial SPECT radiopharmaceutical product from its CMO Montreal facility following the restart of production. It also signed an agreement with a major radiopharmaceutical player to distribute a leading PET diagnostic product through its new PET pharmacies.
Its Allergy Immunotherapy business recorded increased demand in both the US and international markets.
The CDMO Sterile Injectables business secured a master services agreement with a large innovator pharmaceutical company for the manufacturing and commercial supply of a major oncology product. The company also attributed strong growth in this segment to technology transfer revenues from its new and third production lines.
In CRDMO, the company expects revenue growth from the biotech customer segment and custom manufacturing. Its Generics business also registered sharp revenue growth, supported by multiple product launches in FY27.
Meanwhile, Jubilant Pharmova's proprietary novel drugs business presented initial clinical data from its JBI-802 Phase 1/2 trial, showing rapid and sustained dose-dependent reductions in platelet counts, with a manageable safety profile.
Adding to its financial initiatives, Jubilant Pharmova successfully raised Rs 800 crore through non-convertible debentures. The proceeds will be deployed towards debt refinancing and capital expenditure.
The company said it remains on track towards its Vision 2030 goals, with revenue growth continuing across its business segments despite near-term pressure on margins and profitability.